Shattuck Labs (NASDAQ:STTK) Given “Hold” Rating at Needham & Company LLC

Shattuck Labs (NASDAQ:STTK)‘s stock had its “hold” rating reiterated by analysts at Needham & Company LLC in a research note issued on Thursday,Benzinga reports.

A number of other equities research analysts also recently issued reports on STTK. HC Wainwright reissued a “neutral” rating on shares of Shattuck Labs in a report on Thursday. Leerink Partnrs upgraded shares of Shattuck Labs to a “strong-buy” rating in a research note on Monday, March 17th. Finally, Leerink Partners initiated coverage on shares of Shattuck Labs in a report on Monday, March 17th. They issued an “outperform” rating and a $4.00 price target on the stock. Four research analysts have rated the stock with a hold rating, one has assigned a buy rating and two have given a strong buy rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $7.50.

Shattuck Labs Stock Down 9.3 %

STTK traded down $0.11 during trading on Thursday, reaching $1.07. 70,231 shares of the company were exchanged, compared to its average volume of 151,944. Shattuck Labs has a 12-month low of $0.94 and a 12-month high of $11.76. The company’s 50-day moving average is $1.24 and its two-hundred day moving average is $1.51. The company has a market cap of $51.08 million, a price-to-earnings ratio of -0.70 and a beta of 1.66.

Hedge Funds Weigh In On Shattuck Labs

A number of hedge funds and other institutional investors have recently bought and sold shares of the stock. Connor Clark & Lunn Investment Management Ltd. lifted its holdings in shares of Shattuck Labs by 44.1% during the 3rd quarter. Connor Clark & Lunn Investment Management Ltd. now owns 178,228 shares of the company’s stock worth $622,000 after acquiring an additional 54,505 shares during the last quarter. FMR LLC lifted its stake in Shattuck Labs by 0.4% during the third quarter. FMR LLC now owns 7,159,090 shares of the company’s stock worth $24,985,000 after purchasing an additional 26,460 shares during the last quarter. MetLife Investment Management LLC boosted its holdings in shares of Shattuck Labs by 129.1% in the 3rd quarter. MetLife Investment Management LLC now owns 24,596 shares of the company’s stock worth $86,000 after purchasing an additional 13,859 shares in the last quarter. Atom Investors LP bought a new position in shares of Shattuck Labs during the 3rd quarter valued at about $35,000. Finally, Benjamin Edwards Inc. purchased a new position in shares of Shattuck Labs during the 3rd quarter valued at about $61,000. Hedge funds and other institutional investors own 58.74% of the company’s stock.

About Shattuck Labs

Shattuck Labs, Inc, a clinical-stage biotechnology company, develops therapeutics for the treatment of cancer and autoimmune disease in the United States. The company's lead product candidate is SL-172154, which is in Phase 1 clinical trial for the treatment of ovarian, fallopian tube, and peritoneal cancers.